Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Analyst Visit Confirms Growth Potential for Boston Scientific Corporation (BSX), Buy Rating Retained
Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen ... Read More
Analysts project durable growth with many near-term catalysts for Boston Scientific
Analysts remain high on Boston Scientific after a visit to the company's Marlborough, Massachusetts headquarters. Read More
BTIG Reiterates Boston Scientific (BSX) Buy Recommendation
Fintel reports that on November 21, 2025, BTIG reiterated coverage of Boston Scientific (NYSE:BSX) with a Buy recommendation. Analyst Price Forecast Suggests 32.76% Upside As of November 17, 2025, the ... Read More
Advisors Capital Management LLC Acquires 948 Shares of Boston Scientific Corporation $BSX
Advisors Capital Management LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 27.5% during the 1st quarter, according to the company in its most recent filing with the ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus